ANI Pharmaceuticals Inc — Quarterly Cash Flow (NASDAQ:ANIP) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics Dividends

Quarterly Annual

Total assets 1.29 B1.28 B1.29 B1.34 B1.41 B1.44 B Total liabilities 856.58 M855.17 M848.96 M881.39 M902.34 M899.65 M Total equity 405.95 M403.68 M418.62 M436.76 M505.82 M540.72 M Total liabilities & shareholders' equities 1.29 B1.28 B1.29 B1.34 B1.41 B1.44 B Total debt —————— Net debt ——————

Haberler

RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus

PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View

TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line

PRGO Q4 Earnings Miss, Sales Beat, Stock Down on Weak 2026 View

ANI Pharma 4Ç 2025: Nadir hastalık odağı geliri %44 artırdı

ANI Pharma Q4 2025 slides: rare disease shift drives 44% revenue growth

ANI Pharma kazancı $0,36 ile beklentilere göre daha iyi, kâr ise beklentilere göre yüksek

ANI Pharma earnings beat by $0.36, revenue topped estimates

ANI Pharmaceuticals Turns Profit, Rare Disease Sales Surge 50% - ANI Pharmaceuticals (NASDAQ:ANIP)

Brightspring Health Services, BASF, Swiss Re and more set to report Friday

Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up

ANI Pharmaceuticals set to report earnings as Cortrophin drives shift